NDAORALCAPSULEPriority Review
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
Priority Review
ANAFRANIL (clomipramine hydrochloride) by Aurobindo Pharma is clinical pharmacology pharmacodynamics clomipramine (cmi) is presumed to influence obsessive and compulsive behaviors through its effects on serotonergic neuronal transmission. First approved in 1989.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANAFRANIL (clomipramine hydrochloride) is a tricyclic antidepressant that inhibits serotonin reuptake to treat obsessive-compulsive disorder and related conditions. It works by increasing serotonin availability in the brain through blockade of the serotonin transporter. Clomipramine is presumed to influence obsessive and compulsive behaviors through modulation of serotonergic neuronal transmission.
$0.001BPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Medicare spending suggests declining team investment and focus on managed transition to generic.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Clomipramine (CMI) is presumed to influence obsessive and compulsive behaviors through its effects on serotonergic neuronal transmission. The actual neurochemical mechanism is unknown, but CMI's capacity to inhibit the reuptake of serotonin (5-HT) is thought…
Worked on ANAFRANIL at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.